Skip to main content
. 2010 Jan 6;285(11):8234–8243. doi: 10.1074/jbc.M109.065805

FIGURE 7.

FIGURE 7.

Influence of rMASP-2 (MASP2 isoform 1) and rMAP-1 (MASP1 isoform 3) on the MBL- and ficolin-3-mediated complement C4 deposition. Polystyrene plates were coated with either mannan followed by 400 ng/ml rMBL or AcBSA followed by 400 ng/ml rficolin-3. MBL- or ficolin-3-deficient serum was added in dilutions from 0.01 to 2.5%. C4 depositions were measured using a polyclonal antibody to C4 and are given as A490–650 nm values. The error bars indicate two times the standard deviation of double determinations. Approximated concentrations of rMBL, rficolin-3, rMAP-1, and rMASP-2 are given in the figure labels. A–C show MBL-dependent C4 deposition on mannan, whereas D–F show ficolin-3-dependent C4 deposition on AcBSA. A, C4 deposition on a mannan-coated surface incubating rMBL at 400 ng/ml before addition of MBL-deficient serum in different dilutions. The control was without the addition of rMBL. B, dose-dependent enhancing effect of rMASP-2 on the rMBL-mediated C4 deposition. A total of 400 ng/ml of rMBL was preincubated with serial dilutions of rMASP-2 prior to the application of MBL-deficient serum as described under “Experimental Procedures.” C, dose-dependent inhibitory effect of rMAP-1 on the rMBL-mediated C4 deposition. A total of 400 ng/ml of rMBL was preincubated with serial dilutions of rMAP-1 prior to the application of MBL-deficient serum as described under “Experimental Procedures.” D, C4 deposition on an AcBSA-coated surface incubating rficolin-3 at 400 ng/ml before the addition of ficolin-3-deficient serum in different dilutions. The control was without addition of rficolin-3. E, dose-dependent enhancing effect of rMASP-2 on the rficolin-3-mediated C4 deposition. A total of 400 ng/ml of rficolin-3 was preincubated with serial dilutions of rMASP-2 prior to the application of ficolin-3-deficient serum as described under “Experimental Procedures.” F, dose-dependent inhibitory effect of rMAP-1 on the rficolin-3-mediated C4 deposition. A total of 400 ng/ml of rficolin-3 was preincubated with serial dilutions of rMAP-1 prior to the application of ficolin-3-deficient serum as described under “Experimental Procedures.”